 Prem Subramanian
Concepts (436)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Optic Disk | 17 | 2023 | 36 | 6.480 |
Why?
| | Papilledema | 15 | 2022 | 36 | 6.340 |
Why?
| | Optic Nerve Diseases | 15 | 2023 | 32 | 4.820 |
Why?
| | Intracranial Hypertension | 8 | 2023 | 41 | 4.450 |
Why?
| | Optic Neuropathy, Ischemic | 10 | 2023 | 29 | 4.400 |
Why?
| | Pseudotumor Cerebri | 10 | 2023 | 22 | 4.280 |
Why?
| | Tomography, Optical Coherence | 18 | 2023 | 126 | 3.820 |
Why?
| | Visual Fields | 19 | 2022 | 78 | 3.670 |
Why?
| | Vision Disorders | 18 | 2023 | 135 | 3.570 |
Why?
| | Visual Acuity | 18 | 2022 | 272 | 3.260 |
Why?
| | Ophthalmology | 8 | 2024 | 80 | 3.110 |
Why?
| | Abducens Nerve Diseases | 5 | 2022 | 10 | 2.620 |
Why?
| | Optic Neuritis | 8 | 2023 | 37 | 2.620 |
Why?
| | Eye Injuries | 4 | 2021 | 46 | 2.460 |
Why?
| | Hemianopsia | 6 | 2022 | 10 | 2.430 |
Why?
| | Fluorescein Angiography | 10 | 2021 | 103 | 2.330 |
Why?
| | Oculomotor Nerve Diseases | 5 | 2021 | 9 | 2.240 |
Why?
| | Exophthalmos | 4 | 2023 | 19 | 2.180 |
Why?
| | Retinal Ganglion Cells | 10 | 2022 | 92 | 2.030 |
Why?
| | Carotid-Cavernous Sinus Fistula | 4 | 2021 | 9 | 2.010 |
Why?
| | Nerve Fibers | 9 | 2022 | 89 | 1.930 |
Why?
| | Embolization, Therapeutic | 5 | 2021 | 192 | 1.900 |
Why?
| | Eye Diseases, Hereditary | 3 | 2019 | 13 | 1.860 |
Why?
| | Retinal Artery Occlusion | 2 | 2022 | 8 | 1.710 |
Why?
| | Diplopia | 6 | 2023 | 16 | 1.640 |
Why?
| | Ocular Motility Disorders | 2 | 2023 | 27 | 1.530 |
Why?
| | Intraocular Pressure | 9 | 2022 | 275 | 1.490 |
Why?
| | Isaacs Syndrome | 2 | 2023 | 5 | 1.410 |
Why?
| | Graves Ophthalmopathy | 3 | 2023 | 14 | 1.380 |
Why?
| | Astronauts | 4 | 2023 | 19 | 1.360 |
Why?
| | Humans | 123 | 2024 | 118974 | 1.340 |
Why?
| | Orbit | 6 | 2023 | 59 | 1.330 |
Why?
| | Eye Diseases | 4 | 2021 | 77 | 1.330 |
Why?
| | Perceptual Disorders | 2 | 2019 | 21 | 1.310 |
Why?
| | Retina | 5 | 2022 | 278 | 1.250 |
Why?
| | Orbital Diseases | 4 | 2013 | 26 | 1.190 |
Why?
| | Optic Disk Drusen | 4 | 2020 | 5 | 1.170 |
Why?
| | Space Flight | 4 | 2023 | 129 | 1.160 |
Why?
| | Multiple Sclerosis | 3 | 2018 | 384 | 1.140 |
Why?
| | Color Vision Defects | 2 | 2017 | 6 | 1.140 |
Why?
| | Trochlear Nerve Diseases | 3 | 2023 | 6 | 1.100 |
Why?
| | Neurology | 4 | 2021 | 94 | 1.090 |
Why?
| | Orbital Neoplasms | 2 | 2018 | 21 | 1.050 |
Why?
| | Ophthalmic Artery | 3 | 2021 | 7 | 1.050 |
Why?
| | Academies and Institutes | 2 | 2024 | 44 | 1.020 |
Why?
| | Optic Nerve | 5 | 2023 | 65 | 1.010 |
Why?
| | Eye | 3 | 2021 | 106 | 0.970 |
Why?
| | Glaucoma | 6 | 2023 | 202 | 0.970 |
Why?
| | Stroke | 3 | 2017 | 1047 | 0.910 |
Why?
| | Visual Field Tests | 9 | 2020 | 14 | 0.910 |
Why?
| | Orbital Pseudotumor | 2 | 2018 | 3 | 0.880 |
Why?
| | Ophthalmologic Surgical Procedures | 4 | 2018 | 60 | 0.880 |
Why?
| | Intracranial Aneurysm | 2 | 2022 | 99 | 0.880 |
Why?
| | Absorption, Physiological | 1 | 2021 | 5 | 0.850 |
Why?
| | Prostaglandins, Synthetic | 1 | 2021 | 7 | 0.840 |
Why?
| | Embolism | 1 | 2022 | 43 | 0.840 |
Why?
| | Intracranial Pressure | 5 | 2023 | 53 | 0.840 |
Why?
| | Myofibroma | 1 | 2021 | 4 | 0.840 |
Why?
| | Adie Syndrome | 1 | 2021 | 1 | 0.810 |
Why?
| | Cerebral Small Vessel Diseases | 1 | 2021 | 1 | 0.810 |
Why?
| | Meningioma | 3 | 2018 | 82 | 0.800 |
Why?
| | Cerebrospinal Fluid | 1 | 2021 | 93 | 0.800 |
Why?
| | Nasal Mucosa | 1 | 2021 | 97 | 0.790 |
Why?
| | Weapons | 1 | 2021 | 10 | 0.790 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.790 |
Why?
| | Societies, Medical | 2 | 2024 | 703 | 0.780 |
Why?
| | Political Activism | 1 | 2021 | 11 | 0.780 |
Why?
| | Recreation | 1 | 2021 | 26 | 0.780 |
Why?
| | Hallucinations | 1 | 2020 | 29 | 0.770 |
Why?
| | Virtual Reality | 1 | 2021 | 38 | 0.760 |
Why?
| | Adult | 37 | 2023 | 31512 | 0.760 |
Why?
| | Arteriovenous Malformations | 2 | 2011 | 24 | 0.750 |
Why?
| | Male | 50 | 2022 | 57801 | 0.740 |
Why?
| | Glaucoma, Open-Angle | 2 | 2020 | 95 | 0.740 |
Why?
| | Peripheral Nerves | 2 | 2020 | 65 | 0.730 |
Why?
| | Middle Aged | 39 | 2021 | 27617 | 0.730 |
Why?
| | Choroid | 1 | 2020 | 47 | 0.720 |
Why?
| | Macula Lutea | 2 | 2019 | 15 | 0.710 |
Why?
| | Regional Blood Flow | 1 | 2021 | 418 | 0.700 |
Why?
| | Cerebrovascular Circulation | 1 | 2021 | 204 | 0.700 |
Why?
| | Vertigo | 1 | 2019 | 35 | 0.680 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 79 | 0.670 |
Why?
| | Optic Chiasm | 5 | 2021 | 18 | 0.670 |
Why?
| | Optic Atrophy, Hereditary, Leber | 3 | 2023 | 4 | 0.660 |
Why?
| | Sinus Thrombosis, Intracranial | 2 | 2020 | 22 | 0.650 |
Why?
| | Sphenoid Sinus | 1 | 2017 | 9 | 0.640 |
Why?
| | Female | 47 | 2022 | 61565 | 0.630 |
Why?
| | Paranasal Sinus Diseases | 1 | 2017 | 14 | 0.630 |
Why?
| | Reimbursement Mechanisms | 1 | 2018 | 79 | 0.610 |
Why?
| | Cranial Sinuses | 2 | 2014 | 13 | 0.600 |
Why?
| | Contrast Sensitivity | 2 | 2015 | 13 | 0.590 |
Why?
| | Giant Cell Arteritis | 4 | 2022 | 47 | 0.590 |
Why?
| | Meningeal Neoplasms | 2 | 2018 | 90 | 0.580 |
Why?
| | Postural Balance | 1 | 2019 | 184 | 0.570 |
Why?
| | Visual Pathways | 2 | 2013 | 43 | 0.570 |
Why?
| | Retinopathy of Prematurity | 3 | 2023 | 111 | 0.560 |
Why?
| | Aged | 22 | 2022 | 19657 | 0.560 |
Why?
| | Diagnostic Techniques, Ophthalmological | 3 | 2021 | 36 | 0.540 |
Why?
| | Color Perception Tests | 1 | 2015 | 3 | 0.540 |
Why?
| | Arteriovenous Fistula | 2 | 2006 | 29 | 0.540 |
Why?
| | Color Vision | 1 | 2015 | 2 | 0.540 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 2015 | 31 | 0.530 |
Why?
| | Carotid Artery, Internal | 3 | 2021 | 34 | 0.530 |
Why?
| | Therapy, Computer-Assisted | 1 | 2015 | 60 | 0.520 |
Why?
| | Recovery of Function | 2 | 2017 | 604 | 0.510 |
Why?
| | Nervous System Diseases | 3 | 2020 | 261 | 0.510 |
Why?
| | Head and Neck Neoplasms | 1 | 2020 | 471 | 0.500 |
Why?
| | Blindness | 2 | 2015 | 35 | 0.500 |
Why?
| | Aspergillosis | 2 | 2013 | 24 | 0.500 |
Why?
| | Cerebrovascular Disorders | 2 | 2013 | 86 | 0.500 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 610 | 0.490 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2014 | 33 | 0.490 |
Why?
| | Young Adult | 17 | 2020 | 10793 | 0.480 |
Why?
| | Headache | 5 | 2021 | 128 | 0.480 |
Why?
| | Circle of Willis | 1 | 2013 | 6 | 0.470 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 42 | 0.470 |
Why?
| | Brain Injuries, Traumatic | 1 | 2018 | 318 | 0.470 |
Why?
| | Medical Audit | 1 | 2013 | 75 | 0.470 |
Why?
| | Decompression, Surgical | 1 | 2014 | 97 | 0.460 |
Why?
| | Referral and Consultation | 1 | 2018 | 648 | 0.450 |
Why?
| | Ischemic Attack, Transient | 1 | 2013 | 62 | 0.450 |
Why?
| | Magnetic Resonance Imaging | 11 | 2021 | 3174 | 0.450 |
Why?
| | Optic Nerve Neoplasms | 2 | 2021 | 10 | 0.440 |
Why?
| | Medicare | 1 | 2018 | 663 | 0.440 |
Why?
| | Ophthalmologists | 2 | 2024 | 12 | 0.440 |
Why?
| | Retrospective Studies | 18 | 2023 | 12978 | 0.440 |
Why?
| | Skin Neoplasms | 1 | 2020 | 762 | 0.430 |
Why?
| | Cerebral Angiography | 4 | 2021 | 116 | 0.430 |
Why?
| | Lymphangioma | 1 | 2011 | 9 | 0.420 |
Why?
| | Varicose Veins | 1 | 2011 | 15 | 0.410 |
Why?
| | Eye Infections, Fungal | 1 | 2010 | 7 | 0.390 |
Why?
| | Oculomotor Muscles | 2 | 2023 | 42 | 0.390 |
Why?
| | Aspergillus fumigatus | 1 | 2010 | 21 | 0.390 |
Why?
| | Follow-Up Studies | 7 | 2021 | 4596 | 0.370 |
Why?
| | Brain Diseases | 1 | 2011 | 140 | 0.370 |
Why?
| | Algorithms | 6 | 2023 | 1541 | 0.370 |
Why?
| | ROC Curve | 6 | 2021 | 473 | 0.360 |
Why?
| | Cross-Sectional Studies | 7 | 2023 | 4552 | 0.360 |
Why?
| | Practice Patterns, Physicians' | 2 | 2018 | 1200 | 0.350 |
Why?
| | United States | 10 | 2024 | 12555 | 0.340 |
Why?
| | Retinal Vein | 1 | 2008 | 13 | 0.340 |
Why?
| | Military Medicine | 2 | 2008 | 94 | 0.330 |
Why?
| | Cerebrospinal Fluid Proteins | 1 | 2008 | 9 | 0.330 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 942 | 0.330 |
Why?
| | Strabismus | 1 | 2008 | 27 | 0.320 |
Why?
| | Postoperative Complications | 3 | 2013 | 2235 | 0.320 |
Why?
| | Eye Movements | 2 | 2018 | 56 | 0.310 |
Why?
| | Eye Pain | 2 | 2017 | 7 | 0.310 |
Why?
| | Corneal Edema | 1 | 2007 | 5 | 0.310 |
Why?
| | Ophthalmoplegia, Chronic Progressive External | 1 | 2007 | 3 | 0.310 |
Why?
| | Iraq War, 2003-2011 | 1 | 2008 | 151 | 0.310 |
Why?
| | Mitochondrial Myopathies | 1 | 2007 | 5 | 0.310 |
Why?
| | Prostatectomy | 1 | 2007 | 100 | 0.300 |
Why?
| | Brain | 3 | 2021 | 2490 | 0.300 |
Why?
| | Astigmatism | 2 | 2006 | 10 | 0.300 |
Why?
| | Stents | 3 | 2016 | 457 | 0.300 |
Why?
| | Photorefractive Keratectomy | 2 | 2006 | 13 | 0.300 |
Why?
| | Septo-Optic Dysplasia | 1 | 2006 | 3 | 0.290 |
Why?
| | Craniocerebral Trauma | 1 | 2008 | 146 | 0.290 |
Why?
| | Visual Cortex | 1 | 2006 | 40 | 0.280 |
Why?
| | Temporal Arteries | 3 | 2022 | 47 | 0.280 |
Why?
| | Cavernous Sinus | 2 | 2021 | 16 | 0.280 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2008 | 227 | 0.270 |
Why?
| | Prospective Studies | 9 | 2019 | 6471 | 0.270 |
Why?
| | Ophthalmoscopy | 3 | 2021 | 30 | 0.270 |
Why?
| | Carotid Artery Diseases | 1 | 2005 | 58 | 0.270 |
Why?
| | Transverse Sinuses | 2 | 2016 | 8 | 0.260 |
Why?
| | Ocular Hypertension | 3 | 2015 | 60 | 0.260 |
Why?
| | Retinal Artery | 1 | 2004 | 15 | 0.250 |
Why?
| | Retinitis | 1 | 2004 | 17 | 0.250 |
Why?
| | Retinal Vasculitis | 1 | 2004 | 7 | 0.250 |
Why?
| | Peptide Hormones | 1 | 2004 | 8 | 0.250 |
Why?
| | Aneurysm | 1 | 2004 | 32 | 0.250 |
Why?
| | Adolescent | 11 | 2021 | 18480 | 0.250 |
Why?
| | Laser Coagulation | 2 | 2019 | 55 | 0.230 |
Why?
| | Diagnosis, Differential | 3 | 2014 | 1384 | 0.230 |
Why?
| | Eyeglasses | 1 | 2003 | 4 | 0.230 |
Why?
| | Diphosphonates | 1 | 2003 | 50 | 0.230 |
Why?
| | Parvovirinae | 1 | 2022 | 1 | 0.230 |
Why?
| | Physicians | 2 | 2022 | 794 | 0.230 |
Why?
| | Eye Burns | 1 | 2022 | 11 | 0.220 |
Why?
| | Ultrasonography | 2 | 2021 | 716 | 0.220 |
Why?
| | Radiation Injuries | 1 | 2004 | 131 | 0.220 |
Why?
| | Paralysis | 1 | 2023 | 67 | 0.220 |
Why?
| | Myopia | 1 | 2003 | 37 | 0.220 |
Why?
| | Eyelid Diseases | 1 | 2022 | 19 | 0.220 |
Why?
| | Arteries | 2 | 2021 | 250 | 0.220 |
Why?
| | Compartment Syndromes | 1 | 2022 | 38 | 0.220 |
Why?
| | Cornea | 1 | 2003 | 117 | 0.210 |
Why?
| | Fluorometry | 1 | 2021 | 20 | 0.210 |
Why?
| | Oculomotor Nerve | 1 | 2021 | 5 | 0.210 |
Why?
| | Fundus Oculi | 2 | 2020 | 41 | 0.210 |
Why?
| | Dinoprost | 1 | 2021 | 31 | 0.210 |
Why?
| | Administration, Intranasal | 1 | 2021 | 79 | 0.210 |
Why?
| | Endovascular Procedures | 2 | 2018 | 276 | 0.210 |
Why?
| | Skull Base | 1 | 2021 | 44 | 0.210 |
Why?
| | Aged, 80 and over | 5 | 2017 | 6561 | 0.200 |
Why?
| | Blood Pressure | 1 | 2008 | 1664 | 0.200 |
Why?
| | Retinal Vessels | 1 | 2021 | 53 | 0.200 |
Why?
| | Bone Neoplasms | 1 | 2003 | 199 | 0.200 |
Why?
| | Posture | 2 | 2019 | 158 | 0.200 |
Why?
| | Dissent and Disputes | 1 | 2021 | 18 | 0.200 |
Why?
| | Lewy Bodies | 1 | 2020 | 4 | 0.200 |
Why?
| | Ubiquinone | 1 | 2020 | 25 | 0.190 |
Why?
| | Crowding | 1 | 2021 | 38 | 0.190 |
Why?
| | Vision, Ocular | 1 | 2020 | 32 | 0.190 |
Why?
| | Antigens, Viral | 1 | 2021 | 181 | 0.190 |
Why?
| | Wounds and Injuries | 1 | 2008 | 772 | 0.190 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 99 | 0.190 |
Why?
| | Prostatic Neoplasms | 2 | 2007 | 940 | 0.190 |
Why?
| | Treatment Outcome | 8 | 2020 | 9342 | 0.190 |
Why?
| | Macular Degeneration | 1 | 2022 | 151 | 0.190 |
Why?
| | Fovea Centralis | 1 | 2019 | 8 | 0.180 |
Why?
| | Fluorescent Dyes | 1 | 2021 | 316 | 0.180 |
Why?
| | Congresses as Topic | 1 | 2021 | 204 | 0.180 |
Why?
| | Neurosurgical Procedures | 2 | 2018 | 164 | 0.180 |
Why?
| | DNA, Viral | 1 | 2021 | 356 | 0.170 |
Why?
| | Microvessels | 1 | 2020 | 77 | 0.170 |
Why?
| | Risk Factors | 6 | 2023 | 9000 | 0.170 |
Why?
| | Sensitivity and Specificity | 4 | 2022 | 1795 | 0.170 |
Why?
| | Health Surveys | 1 | 2021 | 454 | 0.170 |
Why?
| | Quality of Life | 4 | 2022 | 2366 | 0.170 |
Why?
| | Inflammation | 4 | 2023 | 2566 | 0.170 |
Why?
| | Dizziness | 1 | 2019 | 70 | 0.170 |
Why?
| | Retinal Detachment | 1 | 2019 | 54 | 0.170 |
Why?
| | Ligation | 1 | 2018 | 82 | 0.170 |
Why?
| | Tonometry, Ocular | 3 | 2019 | 83 | 0.170 |
Why?
| | Skull Base Neoplasms | 1 | 2018 | 29 | 0.160 |
Why?
| | Forms and Records Control | 1 | 2018 | 23 | 0.160 |
Why?
| | Transcranial Direct Current Stimulation | 1 | 2017 | 4 | 0.160 |
Why?
| | Healthy Volunteers | 1 | 2019 | 201 | 0.160 |
Why?
| | Periodicals as Topic | 1 | 2020 | 191 | 0.160 |
Why?
| | Capillaries | 1 | 2018 | 103 | 0.160 |
Why?
| | Social Media | 1 | 2020 | 133 | 0.160 |
Why?
| | Child | 7 | 2022 | 19129 | 0.160 |
Why?
| | Angiogenesis Inhibitors | 1 | 2019 | 219 | 0.160 |
Why?
| | Headache Disorders | 1 | 2017 | 12 | 0.150 |
Why?
| | Disease Progression | 3 | 2020 | 2490 | 0.150 |
Why?
| | Herpesvirus 3, Human | 1 | 2021 | 389 | 0.150 |
Why?
| | Betacoronavirus | 1 | 2020 | 254 | 0.150 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 1997 | 26 | 0.150 |
Why?
| | X Chromosome | 1 | 1997 | 47 | 0.150 |
Why?
| | Accidents, Traffic | 1 | 2018 | 178 | 0.150 |
Why?
| | Prevalence | 2 | 2016 | 2326 | 0.150 |
Why?
| | Arteritis | 1 | 2016 | 27 | 0.150 |
Why?
| | Burnout, Professional | 1 | 2022 | 330 | 0.140 |
Why?
| | Machine Learning | 1 | 2020 | 331 | 0.140 |
Why?
| | Area Under Curve | 2 | 2014 | 296 | 0.140 |
Why?
| | Neuronal Plasticity | 2 | 2017 | 219 | 0.140 |
Why?
| | Infant | 5 | 2023 | 8293 | 0.140 |
Why?
| | Education, Medical, Graduate | 1 | 2020 | 399 | 0.140 |
Why?
| | Constriction, Pathologic | 2 | 2014 | 203 | 0.140 |
Why?
| | Activities of Daily Living | 1 | 2019 | 354 | 0.140 |
Why?
| | Abducens Nerve | 1 | 2015 | 3 | 0.140 |
Why?
| | Pandemics | 2 | 2022 | 1355 | 0.130 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 709 | 0.130 |
Why?
| | DNA Replication | 1 | 1997 | 211 | 0.130 |
Why?
| | Animals | 5 | 2021 | 33381 | 0.130 |
Why?
| | Lateral Sinus Thrombosis | 1 | 2015 | 1 | 0.130 |
Why?
| | Recurrence | 1 | 2018 | 975 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 348 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 339 | 0.130 |
Why?
| | Melanoma | 1 | 2021 | 664 | 0.130 |
Why?
| | Myocardial Ischemia | 1 | 2016 | 251 | 0.130 |
Why?
| | Health Policy | 1 | 2018 | 333 | 0.130 |
Why?
| | Gestational Age | 3 | 2023 | 765 | 0.130 |
Why?
| | Telemedicine | 1 | 2023 | 664 | 0.130 |
Why?
| | Case-Control Studies | 2 | 2016 | 3171 | 0.120 |
Why?
| | Syndrome | 3 | 2019 | 344 | 0.120 |
Why?
| | Carbamazepine | 1 | 2013 | 19 | 0.120 |
Why?
| | Incidence | 3 | 2022 | 2424 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1440 | 0.110 |
Why?
| | Cognition | 1 | 2020 | 1024 | 0.110 |
Why?
| | Abscess | 1 | 2013 | 75 | 0.110 |
Why?
| | Reproducibility of Results | 2 | 2018 | 2874 | 0.110 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2012 | 8 | 0.110 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 1974 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 499 | 0.110 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 4908 | 0.110 |
Why?
| | Hemodynamics | 1 | 2016 | 1004 | 0.100 |
Why?
| | Predictive Value of Tests | 2 | 2014 | 1868 | 0.100 |
Why?
| | Vision, Binocular | 1 | 2011 | 15 | 0.100 |
Why?
| | Anticonvulsants | 1 | 2013 | 184 | 0.100 |
Why?
| | Artificial Intelligence | 2 | 2023 | 140 | 0.100 |
Why?
| | DNA Transposable Elements | 1 | 1992 | 102 | 0.100 |
Why?
| | Neonatal Screening | 2 | 2023 | 152 | 0.100 |
Why?
| | Genetic Therapy | 2 | 2023 | 267 | 0.100 |
Why?
| | Penicillin G Benzathine | 1 | 2010 | 1 | 0.100 |
Why?
| | Obesity | 1 | 2004 | 2746 | 0.100 |
Why?
| | Syphilis Serodiagnosis | 1 | 2010 | 3 | 0.100 |
Why?
| | Penicillin G | 1 | 2010 | 7 | 0.100 |
Why?
| | Psychology | 1 | 2011 | 84 | 0.100 |
Why?
| | Histoplasmosis | 1 | 2010 | 15 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1166 | 0.090 |
Why?
| | Military Personnel | 2 | 2008 | 529 | 0.090 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2010 | 112 | 0.090 |
Why?
| | Time Factors | 5 | 2020 | 6412 | 0.090 |
Why?
| | Venous Pressure | 1 | 2008 | 7 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 1992 | 1012 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2023 | 667 | 0.080 |
Why?
| | Birth Weight | 2 | 2023 | 465 | 0.080 |
Why?
| | Iraq | 1 | 2008 | 82 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2017 | 3730 | 0.080 |
Why?
| | Afghanistan | 1 | 2008 | 108 | 0.080 |
Why?
| | Escherichia coli | 1 | 1992 | 758 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2010 | 965 | 0.080 |
Why?
| | Cohort Studies | 2 | 2016 | 5116 | 0.080 |
Why?
| | Lasers, Excimer | 2 | 2006 | 21 | 0.070 |
Why?
| | Infant, Newborn | 3 | 2023 | 5255 | 0.070 |
Why?
| | Darkness | 1 | 2006 | 22 | 0.070 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2006 | 16 | 0.070 |
Why?
| | Functional Laterality | 1 | 2006 | 208 | 0.070 |
Why?
| | Prognosis | 1 | 2013 | 3443 | 0.070 |
Why?
| | Maxillary Artery | 1 | 2005 | 3 | 0.070 |
Why?
| | Mice | 1 | 2021 | 15520 | 0.070 |
Why?
| | Growth Cones | 1 | 2004 | 6 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2013 | 1022 | 0.060 |
Why?
| | Bucladesine | 1 | 2004 | 24 | 0.060 |
Why?
| | Angiography, Digital Subtraction | 1 | 2005 | 46 | 0.060 |
Why?
| | Platinum | 1 | 2005 | 38 | 0.060 |
Why?
| | Retinal Hemorrhage | 1 | 2004 | 18 | 0.060 |
Why?
| | Ganglia, Spinal | 1 | 2004 | 45 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2013 | 2436 | 0.060 |
Why?
| | Veins | 1 | 2005 | 60 | 0.060 |
Why?
| | Body Constitution | 1 | 2004 | 47 | 0.060 |
Why?
| | Ghrelin | 1 | 2004 | 30 | 0.060 |
Why?
| | Nerve Regeneration | 1 | 2004 | 53 | 0.060 |
Why?
| | Stereotaxic Techniques | 1 | 2004 | 28 | 0.060 |
Why?
| | Growth Hormone | 1 | 2004 | 108 | 0.060 |
Why?
| | Tubulin | 1 | 2004 | 122 | 0.060 |
Why?
| | Psychomotor Performance | 1 | 2006 | 290 | 0.060 |
Why?
| | Demography | 1 | 2024 | 274 | 0.060 |
Why?
| | Magnetic Resonance Angiography | 1 | 2005 | 210 | 0.060 |
Why?
| | Equipment Design | 1 | 2005 | 519 | 0.060 |
Why?
| | Leptin | 1 | 2004 | 231 | 0.060 |
Why?
| | Angiography | 1 | 2023 | 185 | 0.050 |
Why?
| | Prednisone | 1 | 2003 | 235 | 0.050 |
Why?
| | Baltimore | 2 | 2012 | 42 | 0.050 |
Why?
| | Methylprednisolone | 1 | 2022 | 84 | 0.050 |
Why?
| | DNA, Mitochondrial | 1 | 2023 | 187 | 0.050 |
Why?
| | Paraffin Embedding | 1 | 2021 | 22 | 0.050 |
Why?
| | Tissue Fixation | 1 | 2021 | 32 | 0.050 |
Why?
| | Formaldehyde | 1 | 2021 | 50 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2023 | 344 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2022 | 302 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2021 | 86 | 0.050 |
Why?
| | Spinal Cord Injuries | 1 | 2004 | 184 | 0.050 |
Why?
| | Firearms | 1 | 2006 | 281 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2010 | 1510 | 0.050 |
Why?
| | Safety | 1 | 2003 | 304 | 0.050 |
Why?
| | Myasthenia Gravis | 1 | 2020 | 19 | 0.050 |
Why?
| | Light | 1 | 2003 | 342 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 144 | 0.050 |
Why?
| | Axial Length, Eye | 1 | 2019 | 9 | 0.050 |
Why?
| | Tertiary Prevention | 1 | 2019 | 3 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 197 | 0.050 |
Why?
| | Anti-Inflammatory Agents | 1 | 2003 | 465 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 89 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4708 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2019 | 46 | 0.040 |
Why?
| | Weight Loss | 1 | 2004 | 655 | 0.040 |
Why?
| | Extraterrestrial Environment | 1 | 2019 | 11 | 0.040 |
Why?
| | India | 1 | 2019 | 141 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1687 | 0.040 |
Why?
| | Academic Medical Centers | 2 | 2012 | 422 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 409 | 0.040 |
Why?
| | Centrifugation | 1 | 2018 | 31 | 0.040 |
Why?
| | Gravity, Altered | 1 | 2018 | 9 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2019 | 227 | 0.040 |
Why?
| | Blood Loss, Surgical | 1 | 2018 | 87 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2023 | 811 | 0.040 |
Why?
| | Child, Preschool | 1 | 2012 | 9491 | 0.040 |
Why?
| | Rotation | 1 | 2018 | 121 | 0.040 |
Why?
| | Acetazolamide | 1 | 2017 | 28 | 0.040 |
Why?
| | Primary Prevention | 1 | 2019 | 185 | 0.040 |
Why?
| | Hybrid Cells | 1 | 1997 | 46 | 0.040 |
Why?
| | Diuretics | 1 | 2017 | 76 | 0.040 |
Why?
| | Cell Line, Transformed | 1 | 1997 | 136 | 0.040 |
Why?
| | Cricetinae | 1 | 1997 | 262 | 0.040 |
Why?
| | Antioxidants | 1 | 2020 | 564 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2019 | 527 | 0.040 |
Why?
| | Body Mass Index | 1 | 2004 | 2092 | 0.040 |
Why?
| | Weight Reduction Programs | 1 | 2017 | 93 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 681 | 0.040 |
Why?
| | Azacitidine | 1 | 1997 | 119 | 0.030 |
Why?
| | Cloning, Molecular | 1 | 1997 | 546 | 0.030 |
Why?
| | Analgesics | 1 | 2017 | 159 | 0.030 |
Why?
| | Infant, Premature | 1 | 2019 | 480 | 0.030 |
Why?
| | Sex Distribution | 1 | 2016 | 351 | 0.030 |
Why?
| | Treatment Failure | 1 | 2016 | 341 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2017 | 280 | 0.030 |
Why?
| | Vision Tests | 1 | 2015 | 15 | 0.030 |
Why?
| | Enzyme Activation | 1 | 1997 | 828 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1597 | 0.030 |
Why?
| | Insulin | 1 | 2004 | 2162 | 0.030 |
Why?
| | Heart Rate | 1 | 2018 | 729 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2014 | 115 | 0.030 |
Why?
| | Itraconazole | 1 | 2013 | 7 | 0.030 |
Why?
| | Vaccination | 1 | 2022 | 1222 | 0.030 |
Why?
| | Immunocompetence | 1 | 2013 | 43 | 0.030 |
Why?
| | Tinnitus | 1 | 2015 | 61 | 0.030 |
Why?
| | Voriconazole | 1 | 2013 | 24 | 0.030 |
Why?
| | Debridement | 1 | 2013 | 79 | 0.030 |
Why?
| | Chromatin | 1 | 1997 | 441 | 0.030 |
Why?
| | Antifungal Agents | 1 | 2013 | 134 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2013 | 93 | 0.030 |
Why?
| | Disease Management | 1 | 2016 | 571 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2004 | 2445 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 1527 | 0.030 |
Why?
| | Mutation | 1 | 2023 | 3457 | 0.030 |
Why?
| | Triazoles | 1 | 2013 | 134 | 0.030 |
Why?
| | DNA Probes | 1 | 1992 | 60 | 0.030 |
Why?
| | Mutagenesis, Insertional | 1 | 1992 | 61 | 0.030 |
Why?
| | Neurosurgery | 1 | 2012 | 29 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1992 | 182 | 0.030 |
Why?
| | Diabetes Complications | 1 | 2013 | 218 | 0.020 |
Why?
| | Neuroimaging | 1 | 2013 | 256 | 0.020 |
Why?
| | History, 20th Century | 1 | 2012 | 281 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 1992 | 381 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 1992 | 510 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 1992 | 314 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 382 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 940 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1691 | 0.020 |
Why?
| | Base Sequence | 1 | 1992 | 2159 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1992 | 2871 | 0.020 |
Why?
| | Coronary Artery Disease | 1 | 2013 | 647 | 0.020 |
Why?
| | Postoperative Period | 1 | 2006 | 309 | 0.020 |
Why?
| | Visual Perception | 1 | 2006 | 141 | 0.020 |
Why?
| | Tissue Transplantation | 1 | 2004 | 11 | 0.020 |
Why?
| | Axonal Transport | 1 | 2004 | 21 | 0.020 |
Why?
| | Growth Inhibitors | 1 | 2004 | 43 | 0.020 |
Why?
| | Hypertension | 1 | 2013 | 1203 | 0.020 |
Why?
| | Up-Regulation | 1 | 2004 | 872 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2478 | 0.010 |
Why?
| | Rats | 1 | 2004 | 5392 | 0.010 |
Why?
|
|
Subramanian's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|